Last reviewed · How we verify

Ronaldo de Matos Esmeraldo, MD — Portfolio Competitive Intelligence Brief

Ronaldo de Matos Esmeraldo, MD pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Low Tacrolimus Low Tacrolimus marketed Calcineurin inhibitor Calcineurin (protein phosphatase 2B) Immunology
Very Low Tacrolimus Very Low Tacrolimus marketed Calcineurin inhibitor Calcineurin (protein phosphatase 2B) Immunology / Transplantation

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Albert Einstein Healthcare Network · 1 shared drug class
  2. Allergan · 1 shared drug class
  3. Andrew B Adams · 1 shared drug class
  4. Armando Torres Ramírez · 1 shared drug class
  5. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  6. Astellas Pharma China, Inc. · 1 shared drug class
  7. Astellas Pharma Europe Ltd. · 1 shared drug class
  8. Al-Azhar University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ronaldo de Matos Esmeraldo, MD:

Cite this brief

Drug Landscape (2026). Ronaldo de Matos Esmeraldo, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ronaldo-de-matos-esmeraldo-md. Accessed 2026-05-16.

Related